Concepedia

Jennifer E. Amengual

JE

Statistics

Publications

32

Citations

1.8K

H-Index

20

Active since

2008

Affiliations

Columbia University Irving Medical Center(Current)

Columbia University

New York University

Emory University

Northwestern University

Jennifer E. Amengual is an author at Columbia University Irving Medical Center specializing in medicine, oncology, and chemotherapy.

ORCID

Publications per year

2008–2023

32

Publications

32

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly et al. · Journal of Clinical Oncology · 2017 · 174 citations

, , +11

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Matko Kalac, Luigi Scotto, Enrica Marchi et al. · Blood · 2011 · 155 citations · Full text

, , +12

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue et al. · Blood · 2017 · 134 citations · Full text

, , +8

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue et al. · Blood · 2019 · 128 citations · Full text

, , +4

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas et al. · The Lancet Oncology · 2017 · 118 citations · Full text

, , +16

1–5 of 32